KR20190011770A - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR20190011770A
KR20190011770A KR1020187037533A KR20187037533A KR20190011770A KR 20190011770 A KR20190011770 A KR 20190011770A KR 1020187037533 A KR1020187037533 A KR 1020187037533A KR 20187037533 A KR20187037533 A KR 20187037533A KR 20190011770 A KR20190011770 A KR 20190011770A
Authority
KR
South Korea
Prior art keywords
cancer
proteide
cpf
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187037533A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 맥기건
휴 그리피스
크리스 페퍼
Original Assignee
뉴카나 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴카나 피엘씨 filed Critical 뉴카나 피엘씨
Priority to KR1020227034733A priority Critical patent/KR20220142538A/ko
Publication of KR20190011770A publication Critical patent/KR20190011770A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187037533A 2016-06-01 2017-05-31 암 치료 Ceased KR20190011770A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227034733A KR20220142538A (ko) 2016-06-01 2017-05-31 암 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1609600.0A GB201609600D0 (en) 2016-06-01 2016-06-01 Cancer treatments
GB1609600.0 2016-06-01
PCT/GB2017/051560 WO2017207993A1 (en) 2016-06-01 2017-05-31 Cancer treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034733A Division KR20220142538A (ko) 2016-06-01 2017-05-31 암 치료

Publications (1)

Publication Number Publication Date
KR20190011770A true KR20190011770A (ko) 2019-02-07

Family

ID=56410849

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187037533A Ceased KR20190011770A (ko) 2016-06-01 2017-05-31 암 치료
KR1020227034733A Ceased KR20220142538A (ko) 2016-06-01 2017-05-31 암 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227034733A Ceased KR20220142538A (ko) 2016-06-01 2017-05-31 암 치료

Country Status (19)

Country Link
US (2) US11400107B2 (cg-RX-API-DMAC7.html)
EP (1) EP3463384A1 (cg-RX-API-DMAC7.html)
JP (2) JP7367910B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190011770A (cg-RX-API-DMAC7.html)
CN (1) CN109562119A (cg-RX-API-DMAC7.html)
AU (1) AU2017273124B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018074981A2 (cg-RX-API-DMAC7.html)
CA (1) CA3025442C (cg-RX-API-DMAC7.html)
CL (2) CL2018003443A1 (cg-RX-API-DMAC7.html)
EA (1) EA038030B1 (cg-RX-API-DMAC7.html)
GB (1) GB201609600D0 (cg-RX-API-DMAC7.html)
IL (1) IL263123B (cg-RX-API-DMAC7.html)
MA (1) MA45129A (cg-RX-API-DMAC7.html)
MX (1) MX2018014840A (cg-RX-API-DMAC7.html)
MY (1) MY199129A (cg-RX-API-DMAC7.html)
PH (1) PH12018502491A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201810196RA (cg-RX-API-DMAC7.html)
WO (1) WO2017207993A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807811B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3031812T3 (en) 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
LT3224268T (lt) 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN113164773B (zh) * 2018-10-17 2025-03-21 廖细斌 6-巯基嘌呤核苷类似物
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
EP2274617A4 (en) 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
DK3031812T3 (en) * 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
WO2015198059A1 (en) * 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
EP3160978B1 (en) * 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
LT3224268T (lt) * 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
SMT201800303T1 (it) 2015-05-14 2018-07-17 NuCana plc Trattamenti per il cancro
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Also Published As

Publication number Publication date
AU2017273124B2 (en) 2022-09-29
JP2022051965A (ja) 2022-04-01
MA45129A (fr) 2021-05-05
JP2019521971A (ja) 2019-08-08
KR20220142538A (ko) 2022-10-21
CA3025442C (en) 2024-02-20
AU2017273124A1 (en) 2018-12-13
CA3025442A1 (en) 2017-12-07
JP7367910B2 (ja) 2023-10-24
BR112018074981A2 (pt) 2019-03-12
GB201609600D0 (en) 2016-07-13
IL263123A (en) 2018-12-31
MY199129A (en) 2023-10-17
WO2017207993A1 (en) 2017-12-07
EP3463384A1 (en) 2019-04-10
SG11201810196RA (en) 2018-12-28
ZA201807811B (en) 2024-05-30
PH12018502491A1 (en) 2019-09-09
IL263123B (en) 2022-09-01
MX2018014840A (es) 2019-03-14
CL2018003443A1 (es) 2019-08-09
CN109562119A (zh) 2019-04-02
EA201892803A1 (ru) 2019-06-28
US20230218655A1 (en) 2023-07-13
US20190374564A1 (en) 2019-12-12
US11400107B2 (en) 2022-08-02
CL2021002669A1 (es) 2022-05-27
EA038030B1 (ru) 2021-06-25

Similar Documents

Publication Publication Date Title
US20230218655A1 (en) Cancer treatments
US20230226092A1 (en) Cancer treatments based on gemcitabine prodrugs
US20100063074A1 (en) Cancer Treatment Method
JP6810763B2 (ja) がん治療
HK1261423A1 (en) Cancer treatments
HK1237283A1 (en) Cancer treatments
HK1237283B (en) Cancer treatments
EA040796B1 (ru) Лечение рака

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200519

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220103

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220711

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220103

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221005

PJ0201 Trial against decision of rejection

Patent event date: 20221005

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220711

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101001815

Request date: 20221005

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101001815; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20221005

Effective date: 20240711

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20240711

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20221005

Decision date: 20240711

Appeal identifier: 2022101001815